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Abstract. 
 
The dystrophin-associated protein complex 
(DAPC) is necessary for maintaining the integrity of 
the muscle cell plasma membrane and may also play a 
role in coordinating signaling events at the cell surface. 
 
The 
 
a
 
-/
 
b
 
-dystroglycan subcomplex of the DAPC forms 
a critical link between the cytoskeleton and the extra-
cellular matrix. A ligand blot overlay assay was used to 
search for novel dystroglycan binding partners in 
 
postsynaptic membranes from 
 
Torpedo
 
 electric organ. 
 
An 
 
z
 
125-kD dystroglycan-binding polypeptide was pu-
riﬁed and shown by peptide microsequencing to be the 
 
Torpedo
 
 ortholog of the small leucine-rich repeat chon-
droitin sulfate proteoglycan biglycan. Biglycan binding 
to 
 
a
 
-dystroglycan was conﬁrmed by coimmunoprecipi-
tation with both native and recombinant 
 
a
 
-dystro-
glycan. The biglycan binding site was mapped to the 
COOH-terminal third of 
 
a
 
-dystroglycan. Glycosylation 
of 
 
a
 
-dystroglycan is not necessary for this interaction, 
but binding is dependent upon the chondroitin sulfate 
side chains of biglycan. In muscle, biglycan is detected 
at both synaptic and nonsynaptic regions. Finally, bigly-
can expression is elevated in muscle from the dystro-
phic 
 
mdx
 
 mouse. These ﬁndings reveal a novel binding 
partner for 
 
a
 
-dystroglycan and demonstrate a novel av-
enue for interaction of the DAPC and the extracellular 
matrix. These results also raise the possibility of a role 
for biglycan in the pathogenesis, and perhaps the treat-
ment, of muscular dystrophy.
Key words: muscular dystrophy • dystrophin-associ-
ated protein complex • chondroitin sulfate proteogly-
can • agrin • neuromuscular junction
 
Introduction
 
The dystrophin-associated protein complex (DAPC)
 
1
 
 links
 
the cytoskeleton to the extracellular matrix (ECM) and is
necessary for maintaining the integrity of the muscle cell
 
plasma membrane. The core DAPC consists of the cy-
toskeletal scaffolding molecule dystrophin and the dys-
troglycan and sarcoglycan transmembrane subcomplexes.
The DAPC also serves to localize key signaling molecules
to the cell surface, at least in part through its associated
syntrophins (Brenman et al., 1996; Bredt, 1998). Mutations
in either dystrophin or any of the sarcoglycans result in
muscular dystrophies characterized by breakdown of the
muscle cell membrane, loss of myofibers, and fibrosis
(Hoffman et al., 1987; Straub and Campbell, 1997). More-
 
over, mutations in the ECM protein laminin-
 
a
 
 2, which as-
sociates with the DAPC on the cell surface, are the basis of
a major congenital muscular dystrophy (Helbling-Leclerc
et al., 1995).
The 
 
a
 
-/
 
b
 
-dystroglycan subcomplex forms a critical struc-
tural link in the DAPC. The transmembrane 
 
b
 
-dystrogly-
can and the wholly extracellular 
 
a
 
-dystroglycan arise by
proteolytic cleavage of a common precursor. The cytoplas-
mic tail of 
 
b
 
-dystroglycan binds dystrophin, while the
highly glycosylated, mucin-like 
 
a
 
-dystroglycan binds to
several ECM elements, including agrin, laminin, and per-
lecan (Ervasti and Campbell, 1993; Bowe et al., 1994; Gee
et al., 1994; Hemler, 1999). This binding to matrix proteins
appears to be essential for assembly of basal lamina, since
mice deficient in dystroglycan fail to form these structures
and die very early in development (Henry and Campbell,
1998). 
 
b
 
-Dystroglycan can bind the signaling adapter mol-
ecule Grb2 and associates indirectly with p125FAK (Yang
et al., 1995; Cavaldesi et al., 1999). Although the signifi-
cance of these associations remains unknown, these bind-
ing properties suggest that dystroglycan may also serve to
localize signaling molecules to the cell surface.
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Several lines of evidence suggest that dystroglycan may
also function in postsynaptic differentiation. 
 
a
 
-Dystrogly-
can binds the synapse organizing molecule agrin (Bowe et al.,
1994; Campanelli et al., 1994; Gee et al., 1994; Sugiyama
et al., 1994; O’Toole et al., 1996; reviewed in Fallon and
Hall, 1994), and 
 
b
 
-dystroglycan binds to the acetylcholine
receptor (AChR)-associated protein, rapsyn (Cartaud et al.,
1998). Further, agrin-induced AChR clustering is mark-
edly decreased in muscle cells expressing reduced levels of
dystroglycan (Montanaro et al., 1998). The precise role of
dystroglycan in this process is unknown. Currently avail-
able evidence suggests that dystroglycan is not part of the
primary agrin receptor, but rather may play a structural
role in the organization of postsynaptic specializations
(Gesemann et al., 1995; Glass et al., 1996; Jacobson et al.,
1998).
The realm of dystroglycan function ranges far beyond
muscle. As noted above, mice defective in dystroglycan
die long before muscle differentiation. In a surprising de-
velopment, 
 
a
 
-dystroglycan in nonmuscle cells has been
shown to function as a receptor for Lassa Fever and cho-
riomeningitis fever viruses (Cao et al., 1998), and on
Schwann cells, as a coreceptor for 
 
Mycobacterium leprae
 
(Rambukkana et al., 1998). Dystroglycan is also abundant
in brain, but its function there is not understood (Gorecki
et al., 1994; Smalheiser and Kim, 1995).
 
a
 
-Dystroglycan is comprised of three known domains.
An NH
 
2
 
-terminal domain folds into an autonomous glob-
ular configuration (Brancaccio et al., 1995). The middle
third of the protein is serine- and threonine-rich and is
highly glycosylated (Brancaccio et al., 1997). Indeed, the
core molecular weight of 
 
a
 
-dystroglycan is 
 
z
 
68 kD, but
the native molecule migrates on SDS-PAGE as a polydis-
perse band whose size ranges from 120–190 kD, depend-
ing upon the species and tissue source (Ervasti and
Campbell, 1993; Bowe et al., 1994; Gee et al., 1994; Mat-
sumura et al., 1997). Glycosylation of 
 
a
 
-dystroglycan,
probably in this middle third, is essential for its laminin-
and agrin-binding properties. Until the present report,
there have been no known structural motifs nor functions
associated with the COOH-terminal third of the mole-
cule.
While it is clear that dystroglycan and the DAPC play
crucial roles in a variety of processes in muscle, as well as
in other tissues, the underlying mechanisms remain ob-
scure. One essential step towards elucidating these func-
tions is to identify and characterize novel dystroglycan-
binding molecules. We therefore developed a ligand blot
overlay assay to search for such binding partners in synap-
tic membranes from 
 
Torpedo
 
 electric organ. We purified
one dystroglycan-binding molecule and identified it as the
small leucine-rich repeat chondroitin sulfate proteoglycan
biglycan. We have mapped the binding site to the COOH-
terminal third of 
 
a
 
-dystroglycan. Although glycosylation
of 
 
a
 
-dystroglycan is not necessary for this interaction,
binding is dependent on the biglycan chondroitin sulfate
side chains. In muscle, biglycan is detected at both synap-
tic and nonsynaptic regions. Finally, we provide evidence
that biglycan expression is elevated in the dystrophic 
 
mdx
 
mouse. These findings thus reveal a novel binding partner
for 
 
a
 
-dystroglycan, and raise the possibility of a role for
biglycan in muscular dystrophy.
 
Materials and Methods
 
Membrane Preparation and Solubilization of DAG-125
 
Postsynaptic and nonsynaptic membrane fractions were prepared by su-
crose density centrifugation from 
 
Torpedo
 
 electric organ as previously de-
scribed (Bowe et al., 1994). All handling of membranes and protein was
performed at 4
 
8
 
C. To solubilize DAG-125 (dystroglycan-associated glyco-
protein, 125 kD), synaptic membranes were centrifuged at 100,000 
 
g
 
 for 1 h
and resuspended in ddH
 
2
 
O. The pH was adjusted to 11.0 or 12.0 (as indi-
cated) with NaOH, and the membranes stirred for 1 h. Insoluble material
was removed by centrifugation at 100,000 
 
g
 
 for 1 h. The alkaline extract
was neutralized with 10 mM Tris-HCl and adjusted to pH 7.4. DAG-125
remained soluble under these conditions, as determined by resistance to
pelleting during a second centrifugation.
 
In Vitro Transcription/Translation
 
The in vitro expression plasmids encoding DG
 
1-891 
 
and DG
 
345-891 
 
(human
dystroglycan sequence) in the in vitro expression vector, pMGT, devel-
oped by A. Ahn (Ahn and Kunkel, 1995), were generously provided by
Lou Kunkel (Children’s Hospital, Boston, MA). Additional in vitro ex-
pression plasmids used in this study were prepared by PCR-based sub-
cloning of these inserts. The PCR primers included restriction sites for re-
ligation into the EcoRI site of pMGT. Dystroglycan protein fragments
were generated by in vitro transcription/translation using the Promega
TNT T7 coupled reticulocyte system as per the manufacturer’s instruc-
tions. For protein to be used in ligand blot overlay assay, the reaction mix-
ture contained [
 
35
 
S]methionine (with no unlabeled methionine). After in-
cubation for 2 h, the reaction mixture was passed over Bio-Spin desalting
columns (BioRad) to remove salts and unincorporated amino acids.
 
Ligand Blot Overlay Assays
 
Membrane proteins were separated by SDS-PAGE (5–15% gradient gel)
and transferred to nitrocellulose. To detect dystroglycan-binding proteins,
the nitrocellulose was rinsed and blocked for 3 h in HBSS containing 1 mM
CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 1% BSA, 1% nonfat dry milk, 1 mM DTT, 10 mM
Hepes, pH 7.4, and was then incubated overnight in the same buffer con-
taining [
 
35
 
S]methionine-labeled dystroglycan fragments produced by in
vitro transcription/translation (see above). Blots were rinsed and dried,
and bound dystroglycan fragments were visualized by autoradiography.
To detect dystroglycan present in the SDS-PAGE sample, an agrin blot
overlay assay was performed essentially as described in O’Toole et al.
(1996). In brief, the nitrocellulose was rinsed and blocked for 3 h in
Hepes-buffered MEM supplemented with 1% BSA and 10% horse se-
rum. It was then incubated for 4 h in this buffer containing recombinant
rat agrin (isoform A
 
0
 
B
 
0
 
, prepared as described in O’Toole et al., 1996),
followed by a second layer containing 1 
 
m
 
g/ml antiagrin antibody 
 
125
 
I-
Mab-131 (Stressgen Laboratories). Bound antiagrin antibody was visual-
ized by autoradiography.
 
Recombinant Dystroglycan from Bacteria
 
A fusion protein of glutathione S-transferase (GST) and amino acids (aa)
345–653 of dystroglycan was produced by using PCR-based subcloning to
introduce dystroglycan coding sequence into the bacterial protein expres-
sion vector, pGEX-1
 
l
 
T (Pharmacia Biotech). The resulting bacterial ex-
pression plasmid, pGST-DG
 
345-653
 
, was then introduced into the 
 
Escheri-
chia coli
 
 strain BL21 and expressed fusion protein recovered from the
cytoplasmic fraction as per manufacturer’s instructions. Control protein
(GST) was obtained using pGEX-1
 
l
 
T.
 
Purification and Identification of DAG-125 (Biglycan)
 
Postsynaptic-rich membrane fractions were first preextracted with 25 mM
 
N
 
-octyl-
 
b
 
-
 
D
 
-glucopyranoside to remove detergent-soluble proteins. The
bulk of 
 
a
 
- and 
 
b
 
-dystroglycan is solubilized in this mild detergent (Bowe
et al., 1994). DAG-125 was then solubilized by alkaline extraction (pH
12.0). The alkaline extract was diluted in SEN buffer (20 mM Tris-HCl,
100 mM NaCl, 23 
 
m
 
g/ml aprotinin, 0.5 
 
m
 
g/ml leupeptin, 5 mM benzami-
dine, 0.7 
 
m
 
g/ml pepstatin A, 1 mM phenylmethylsulfonylflouride, 0.02%
azide, and 0.1% Tween 20, pH 7.6) and recentrifuged to remove any pro-
teins precipitating upon neutralization. The extract remained in SEN
buffer for the remainder of the purification, with only the NaCl concentra- 
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tion changed as indicated. The extract was passed over a mAb3B3 column
(Bowe et al., 1994) to remove the small amount of residual, detergent-
insoluble 
 
a
 
-dystroglycan. Further analysis of these fractions revealed that
this 
 
a
 
-dystroglycan was bound to biglycan (see Fig. 2 c); however, since
there was relatively little 
 
a
 
-dystroglycan in the alkaline extract, the major-
ity of the biglycan flowed through the mAb3B3 column. The flow-through
was passed over a combined, non-DAG-125–binding lectin–agarose col-
umn (peanut agglutinin and ulex europaeus agglutinin I; Vector Labora-
tories, Inc.) as a second preclear. The flow-through was next applied to a
column of chondroitin sulfate-agarose. The chondroitin sulfate-agarose
column was prepared by coupling chondroitin sulfate B (Sigma Chemical
Co.; #C-3788) to 
 
v
 
-aminohexyl-agarose (Sigma Chemical Co.) activated
with N-ethyl-N
 
9
 
-(3-dimethylaminopropyl)-carbodiimide (Sigma Chemi-
cal Co.). After incubation with the lectin column flow-through, the chon-
droitin sulfate column was washed extensively and eluted with a 0.1–2.0 M
NaCl gradient. DAG-125 eluted in 0.3–0.65 M NaCl. These fractions were
pooled, diluted to 0.3 M NaCl, and applied to a heparin-agarose column
(Sigma Chemical Co.; #H-0402). The column was washed and eluted with
a 0.3–2.0 M NaCl gradient. DAG-125 eluted in 0.6–0.85 M NaCl. These
fractions were pooled, concentrated by ethanol precipitation, redissolved
in SDS-PAGE sample buffer, separated on a 5–15% gradient gel, and
transferred to a PVDF membrane. A portion of the PVDF membrane was
analyzed for DAG-125 by blot overlay and the remainder was transiently
stained with Ponceau S. Regions of the blot bearing DAG-125 were sub-
jected to tryptic digestion, HPLC analysis, and peptide microsequencing
as described previously (Bowe et al., 1994).
 
Enzymatic Digestions
 
Enzyme treatments were carried out on alkaline-extracted 
 
Torpedo
 
 elec-
tric organ synaptic membrane proteins at 37
 
8
 
C overnight. Enzymes, final
concentration, supplier, and catalog numbers are listed in Table I. All
reactions were performed in the protease inhibitors present in SEN
buffer, with the addition of 1 mM EDTA, 10 mM N-ethylmaleimide, and
0.8% mouse serum albumin. Chondroitinases (all forms) were buffered
with 100 mM Tris-acetate (pH 8.0). Hyaluronidase and keratanase were
buffered with 50 mM sodium acetate (pH 5.0). Heparinases (I, II, and III),
chondro-4-sulfatase, and chondro-6-sulfatase were buffered with 10 mM
NaPO
 
4
 
 (pH 7.4). N-Glycanase, O-glycanase, neuraminidase, 
 
a
 
-N-acetyl-
galactosaminidase, and 
 
b
 
-N-acetylglucosaminidase, were buffered with 50
mM Tris-HCl (pH 7.3). Control treatments included buffers and protease
inhibitors without added enzymes.
 
Recombinant Biglycan
 
P16, a cloning plasmid consisting of pBluescript containing cDNA encod-
ing human biglycan, was kindly provided by Larry Fisher (National Insti-
tute of Dental Research, National Institutes of Health, Bethesda, MD;
Fisher et al., 1989). The sequence coding for the mature secreted protein
(aa 38–368) was amplified by PCR and subcloned into the bacterial ex-
pression vector pQE9 (Qiagen). The resulting plasmid, pQE-biglycan,
adds the sequence MRGSHHHHHHGS to the NH
 
2
 
 terminus. Recombi-
nant protein was produced in 
 
E. coli
 
 strain M15[pREP4]. Uninduced bac-
teria provided control protein. Induced or noninduced bacteria were iso-
lated by centrifugation and resuspended in SDS-PAGE sample buffer for
analysis by ligand blot overlay.
 
Histology
 
Cryostat sections (10 
 
m
 
m) of leg muscle from fresh-frozen wild-type (C57
BL) and 
 
mdx
 
 mice were mounted on the same slide and fixed and treated
with chondroitinase, essentially as described in Bianco et al. (1990). Pri-
mary antibodies were antibiglycan (LF-106; generously provided by
L. Fisher) diluted in PBS containing 5% BSA, 1% normal goat or horse
serum, and 0.1% Triton X-100. Incubation in primary antibodies or non-
immune control serum proceeded overnight at 4
 
8
 
C. Except where noted,
all subsequent steps were performed at room temperature. Bound anti-
bodies were detected with Cy3-labeled anti-rabbit Ig (Jackson Laborato-
ries). For double-labeling, sections were first fixed for 5 min in 1% formal-
dehyde, rinsed, and incubated in fluorescein-conjugated 
 
a
 
-bungarotoxin
(Molecular Probes, Inc.) for 1 h. The sections were then washed, fixed,
treated with chondroitinase, and stained for biglycan as described above.
Sections were air-dried, mounted in Citifluor (Ted Pella, Redding, CA)
and examined on a Nikon Eclipse microscope. Images were acquired on a
cooled CCD camera using IPLab Spectrum software, and then imported
 
to Adobe Photoshop. Images from wild-type and 
 
mdx
 
 muscle were ac-
quired and processed for printing under identical conditions.
 
Results
 
Characterization of a Dystroglycan-binding
Protein, DAG-125
 
To identify novel dystroglycan-binding partners, we devel-
oped a ligand blot overlay assay. 
 
Torpedo
 
 electric organ
membrane proteins were separated by SDS-PAGE and
transferred to nitrocellulose. The blots were then probed
with in vitro translated, [
 
35
 
S]methionine-labeled dystrogly-
can fragments. 
 
a
 
- and 
 
b
 
-dystroglycan are encoded by a sin-
gle polypeptide that is cleaved posttranslationally to yield
the mature polypeptides (Fig. 1; Ibraghimov et al., 1992;
Bowe et al., 1994). Dystroglycan fragments that included
the 
 
a
 
-dystroglycan region bound to an 
 
z
 
125-kD, highly
glycosylated, polypeptide (Fig. 1) to which we gave the
working name DAG-125. Further, DAG-125 is enriched
in postsynaptic membrane fractions from 
 
Torpedo
 
 electric
organ compared with nonsynaptic membranes.
 
Coprecipitation of 
 
a
 
-Dystroglycan and DAG-125
 
We confirmed the association between 
 
a
 
-dystroglycan and
DAG-125 using solution binding. Fig. 2 shows that DAG-
125 coprecipitates with both in vitro translated dystrogly-
can and bacterially produced GST–dystroglycan fusion
protein. Finally, we asked if DAG-125 binds to native dys-
troglycan. Alkaline extracts of 
 
Torpedo
 
 electric organ
membranes contain both DAG-125 and 
 
a
 
-dystroglycan.
We applied this extract to agarose columns conjugated to
either control antibody or to an anti-
 
Torpedo
 
 dystroglycan
mAb (mAb3B3; Bowe et al., 1994). DAG-125 was specifi-
cally coprecipitated with native 
 
a
 
-dystroglycan (Fig. 2 c).
Thus, the binding of DAG-125 to 
 
a
 
-dystroglycan observed
by ligand blot overlay was confirmed using three different
coprecipitation methods. Moreover, an 
 
a
 
-dystroglycan–
biglycan complex can be immunoprecipitated from ex-
tracts of synaptic membranes.
 
Determination of the DAG-125–binding Domain
of 
 
a
 
-Dystroglycan
 
We next sought to determine the region of dystroglycan
that mediates binding to DAG-125. We generated a panel
of dystroglycan fragments by in vitro translation (Fig. 1 b)
and tested the ability of each to bind DAG-125 using the
ligand blot overlay assay. The COOH-terminal one-third
of 
 
a
 
-dystroglycan is sufficient to bind DAG-125. Weak
binding was observed to a fragment comprised of the mid-
dle third of the molecule, suggesting that a contribution
from this region is also possible. The ectodomain of 
 
b
 
-dys-
troglycan did not bind to DAG-125. Moreover, these frag-
ments were produced under conditions where the poly-
peptides are not glycosylated. Therefore, carbohydrate
side chains on dystroglycan are not necessary for its bind-
ing to DAG-125. We conclude that the major binding do-
main is contained in 
 
z
 
150-aa region of dystroglycan. The
location of this domain and the lack of a carbohydrate re-
quirement indicate that 
 
a
 
-dystroglycan’s binding site for
biglycan is distinct from that mediating association with
agrin, laminin, and perlecan (see Discussion). 
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Identification of DAG-125 as Biglycan
 
We next identified DAG-125. Although DAG-125 copuri-
fied with postsynaptic membranes, it was insoluble in all
nonionic detergents tested, including Triton X-100 and
 
N
 
-octyl-
 
b
 
-
 
D
 
-glucopyranoside, both of which efficiently ex-
tract 
 
a
 
-/
 
b
 
-dystroglycan from these membranes (Bowe et al.,
1994; Deyst et al., 1995). We determined that even without
detergent, 
 
z
 
50% of DAG-125 could be extracted at pH
11, and near-complete solubilization was achieved by a
short pH 12 treatment (see Fig 1 a). Importantly, DAG-
125 remained soluble when returned to neutral pH. We
developed a purification protocol (see Materials and
Methods) based upon these properties and the findings
that DAG-125 binds to both heparin and chondroitin sul-
fate columns (data not shown). We estimated the final pu-
rity of DAG-125 to be 
 
z
 
30%. This material was separated
by SDS-PAGE, blotted to PVDF, and two regions of the
DAG-125 band were excised and digested with trypsin.
HPLC analysis showed that the two regions (Fig. 3 a, see
U and L) had identical peptide maps (data not shown).
This finding established the purity of the DAG-125 in
these regions and also indicated that the polydisperse
 
DAG-125 band arises from the heterogeneous glycosyla-
tion of a common polypeptide core. We then sequenced
three tryptic peptides and found that all were highly ho-
mologous to mammalian biglycan, with an overall 76%
identity (Fig. 3 b). We thus conclude that DAG-125 is a
 
Torpedo orthologue of mammalian biglycan.
The Role of Biglycan Chondroitin Sulfate Chains in 
Binding to a-Dystroglycan
Mammalian biglycan is often substituted with chondroitin
sulfate. We therefore asked if Torpedo biglycan is also a
chondroitin sulfate proteoglycan, and whether glycosyla-
tion is important for its binding to a-dystroglycan. We di-
gested DAG-125 with various glycosidases and glycosami-
noglycanases and analyzed the products by a-dystroglycan
ligand blot overlay (Fig. 4; Table I). Removal of chon-
droitin sulfate side chains abolished the binding to a-dystro-
glycan. Chondroitinase B (specific for dermatan sulfate)
had a much smaller effect compared with chondroitinases
whose activity included chondroitin sulfate A and C.
No other glycosidase or glycosaminoglycanase treatment
had a detectable effect on a-dystroglycan binding (Table
Figure 1. a, Initial characterization of DAG-125. In vitro translated dystroglycan fragments were used to probe the indicated membrane
fractions from Torpedo electric organ. The subscripts indicate the amino acid numbering for the human sequence (see b for the domain
structure of the dystroglycans and the position of these fragments). Lanes 1 and 2, A polydisperse membrane protein (DAG-125) binds
to an extracellular portion of dystroglycan. The extracellular domain of dystroglycan (lane 1, DG1-750) bound to DAG-125, whereas the
intracellular portion of dystroglycan (lane 2, DG776-891) did not. The region of negativity in the center of the polydisperse DAG-125
band is due to a high abundance, nonbinding protein that does not copurify with DAG-125 (see lanes 5–7). Lanes 3 and 4, DAG-125 is
enriched in synaptic as compared with nonsynaptic membranes. Equivalent amounts of protein from each membrane fraction were
loaded in both lanes. Lanes 5–7, DAG-125 can be extracted from the membrane by alkaline treatment. Synaptic membranes were ex-
tracted at pH 12 and the insoluble (lane 6) and soluble (lane 7) fractions were analyzed. Greater than 90% of DAG-125 is solubilized by
pH 12.0 treatment. b, Mapping of the DAG-125–binding region of dystroglycan. A schematic diagram of the in vitro translated recom-
binant dystroglycan fragments used to probe DAG-125 by blot overlay is shown. The COOH-terminal one-third of a-dystroglycan
binds DAG-125. A small contribution from the middle third of a-dystroglycan is also possible. b-Dystroglycan does not appear to con-
tribute to binding of DAG-125.Bowe et al. Biglycan Associates with a-Dystroglycan 805
I). Several lines of evidence indicate that the effects of
chondroitinase digestion are due to chondroitinase activity
and not to contaminating proteases: the digestions were
performed in a cocktail of protease inhibitors (see Materi-
als and Methods); the same result was seen with four dif-
ferent preparations of chondroitinase, including two which
had been affinity-purified to remove proteases; and the ef-
fect was prevented by addition of 5 mM Zn21, an inhibitor
of chondroitinase, but not of proteases. We conclude that
biglycan from Torpedo synaptic membranes is substituted
with chondroitin sulfate chains, which are predominantly
chondroitin sulfate A and/or C. Finally, chondroitin sul-
fate substitution of biglycan is necessary for binding to
dystroglycan.
Figure 2. Coprecipitation of
DAG-125 and dystroglycan
(aDG). DAG-125 was solu-
bilized by alkaline treat-
ment, neutralized, and incu-
bated with column matrices
and recombinant or native
dystroglycan as indicated.
The input material and elu-
ates from the beads were an-
alyzed by ligand blot overlay
assay for the presence of
DAG-125 (35S-DG345-653 as
probe) or native a-dystro-
glycan (agrin overlay, see
Materials and Methods). a,
Coimmunoprecipitation of
DAG-125 and in vitro syn-
thesized dystroglycan. DAG-
125 was incubated with goat
anti–mouse Ig-conjugated
agarose beads in the presence or absence of in vitro translated dystroglycan polypeptide (DG345-750) and/or antidystroglycan mAb
(NCL-b-DG; Novocastra). DAG-125 coprecipitated with dystroglycan plus antidystroglycan antibody (lane 5), but was not precipitated
in the absence of either or both (lanes 2–4). b, Coaffinity precipitation of DAG-125 and bacterially produced dystroglycan. DAG-125
was incubated with glutathione Sepharose beads that had been preincubated with either bacterially produced GST or a bacterially pro-
duced GST–dystroglycan fusion protein (GST–DG345-653). DAG-125 was coprecipitated with the dystroglycan fusion protein (lane 3),
but not with GST alone (lane 2). c, Coimmunoprecipitation of DAG-125 and native a-dystroglycan. DAG-125 and a-dystroglycan were
solubilized by alkaline treatment, and incubated with agarose beads conjugated to either normal mouse Ig (NMIg) or anti-Torpedo dys-
troglycan mAb, mAb3B3. Native a-dystroglycan and DAG-125 were coprecipitated by the antidystroglycan antibody (lanes 3 and 6),
but not by control antibody (lanes 2 and 5). Western blots indicate that mAb3B3 does not recognize DAG-125 (data not shown; see
Bowe et al., 1994).
Table I. The Role of Biglycan Glycosylation in Binding to a-Dystroglycan
Enzyme Inhibits binding? Enzyme concentration Source Catalog #
U/ml
Chondroitinase ABC 1 0.5 Sigma Chemical Co. C-2905
Chondroitinase ABC 15 mM ZnCl2 2 0.5 Sigma Chemical Co. C-2905
Chondroitinase ABC, protease-free 1 0.5 Sigma Chemical Co. C-3667
Chondroitinase ABC, protease-free 1 0.5 Roche 1080717
Chondroitinase AC 1 0.5 Sigma Chemical Co. C-2780
Chondroitinase B 6 25 Sigma Chemical Co. C-8058
Heparinase I 2 25 Sigma Chemical Co H-2519
Heparinase II 2 5 Sigma Chemical Co H-3812
Heparinase III (heparitinase) 2 5 Sigma Chemical Co. H-8891
Chondro-4-sulfatase 6 0.5 Sigma Chemical Co. C-2655
Chondro-6-sulfatase 2 0.5 Sigma Chemical Co C-2655
Keratanase 2 0.02 Roche 982954
a-N-acetylgalactosaminidase 2 2 Sigma Chemical Co A-9763
b-N-acetylglucosaminidase 2 8 Sigma Chemical Co A-2264
N-Glycanase 2 15 Genzyme Corp. N-Gly-1
O-Glycanase 2 0.03 Genzyme Corp. B2950
Neuraminidase 2 1 Genzyme Corp. NSS-1The Journal of Cell Biology, Volume 148, 2000 806
We next tested the binding of a-dystroglycan to biglycan
derived from a variety of sources, as well as to decorin, a
small leucine-rich proteoglycan that is z50% identical to
biglycan. Bacterially expressed biglycan, which contains
no chondroitin sulfate side chains, did not bind a-dystro-
glycan (Fig. 5), consistent with a requirement for chon-
droitin sulfate chains. Biglycan purified from articular car-
tilage bound a-dystroglycan poorly, even at .100-fold
higher loading than that used for Torpedo biglycan analy-
sis. These findings indicate that specific chondroitin sulfate
chains are required to mediate a-dystroglycan binding to
biglycan. Note that these experiments show that chon-
droitin sulfate side chains are necessary for biglycan–
a-dystroglycan binding, but they do not establish whether
or not they are sufficient. Studies to determine the possi-
ble contribution of the biglycan core to this binding are
underway.
Biglycan Is Expressed at Synaptic and Nonsynaptic 
Regions and Is Upregulated in Dystrophic Muscle
Previous reports have shown that biglycan mRNA and
protein are expressed in muscle (Bianco et al., 1990; Bosse
et al., 1993). Since we purified biglycan from synaptic
membranes, we asked whether it is also expressed at the
neuromuscular junction. Biglycan is localized around the
periphery of the muscle fiber and at all synapses. Further,
biglycan is enriched at a subset of neuromuscular junctions
(Fig. 6). Finally, since biglycan binds to a component of
the DAPC, we asked whether or not its expression was al-
tered in a mouse model of muscular dystrophy where dys-
Figure 3. Purification of
DAG-125 and its identifica-
tion as biglycan. a, Blot over-
lay analysis of DAG-125 in
selected purification steps.
DAG-125 was purified using
biochemical and affinity
methods before performing
peptide microsequencing.
Represented are the initial
(synaptic membrane protein,
lane 1), middle (input to
chondroitin sulfate column,
lane 2), and final (concen-
trated eluate from heparin
sulfate column, lane 3) steps
of purification. See Materials
and Methods for details of
the purification scheme. The
final purified product was
subjected to SDS-PAGE and
blotted to PVDF. An upper
(U) and a lower (L) region of
the Ponceau-stained mem-
brane was excised and di-
gested with trypsin. The
released peptides were ana-
lyzed by HPLC using a C8 column and UV detection. The column profiles were virtually identical, indicating that the polydisperse band
is due to the presence of a single, heterogeneously glycosylated protein. b, Peptide microsequencing of DAG-125. Three peptides from
the trypsin digest were collected as fractions from the HPLC analysis and subjected to automated Edman degradation. The sequences
obtained were compared with public databases. The alignment of the Torpedo DAG-125 peptides to the deduced sequence of human
biglycan is shown (aa 241–249, 258–266, and 330–348). c, Domain structure of human biglycan (Fisher et al., 1989; Hocking et al., 1998).
Biglycan is one of a family of small leucine-rich repeat proteins. It consists of a prepropeptide that is not present in the mature polypep-
tide. This domain is followed by a short unique sequence with two chondroitin sulfate attachment sites (shown as stacked beads). There
are two pairs and one pair of disulfide-linked cysteines at the NH2- and COOH-terminal domains, respectively. Finally, the bulk of the
protein is comprised of ten (or 11, depending upon the classification of the region within the COOH-terminal cysteine pair) leucine-rich
repeats. The position of the three Torpedo peptides relative to the human sequence is indicated by horizontal lines.
Figure 4. Analysis of Torpedo biglycan
glycosylation. Alkaline-solubilized syn-
aptic membrane proteins were di-
gested as indicated, in the presence of
protease inhibitors, and then analyzed
for dystroglycan binding by blot over-
lay assay with 35S-DG345-653. Both
chondroitinase ABC and chondroiti-
nase AC greatly reduced the binding
of dystroglycan to DAG-125/Torpedo
biglycan. Chondroitinase B, which de-
grades dermatan sulfate, had a much
smaller effect. See also Table I.Bowe et al. Biglycan Associates with a-Dystroglycan 807
trophin is absent, mdx. We examined adult mice, which
contain almost exclusively regenerated muscle fibers that
survive due to utrophin compensation (Grady et al., 1997).
Immunostaining revealed that the level of biglycan ex-
pressed in mdx muscle is elevated compared with control
animals (Fig. 7). These observations raise the possibility
that biglycan could be part of the compensatory mecha-
nism that allows survival of dystrophin-negative muscle
fibers.
Discussion
In this paper, we report the identification and character-
ization of a novel a-dystroglycan binding protein from
postsynaptic membranes of Torpedo electric organ and
provide evidence that it is the small leucine-rich repeat
proteoglycan (SLRP) biglycan. Mapping studies indicate
that the biglycan binding site on a-dystroglycan is distinct
from that of its previously described ligands, laminin,
agrin, and perlecan (Figs. 1 and 8). Moreover, the involve-
ment of biglycan’s chondroitin sulfate side chains in bind-
ing to a-dystroglycan is of particular interest in view of a
large body of evidence implicating chondroitin sulfate pro-
teoglycans in synaptogenesis. Finally, the association of
biglycan with a-dystroglycan, coupled with its upregula-
tion in dystrophic muscle, suggest that biglycan could play
a role in normal DAPC function and perhaps in the patho-
physiological responses of dystrophic muscle.
Several lines of evidence indicate that biglycan is an
a-dystroglycan–binding protein. We demonstrated this in-
teraction using two assays: blot overlay and solution bind-
ing. Further, we showed that several forms of a-dystrogly-
can, in vitro translated, bacterially produced, and native,
bind to biglycan. Biglycan and a-dystroglycan are both en-
riched in postsynaptic membranes of Torpedo electric or-
gan (Figs. 1 and 2; see also Bowe et al., 1994). Importantly,
biglycan–a-dystroglycan complexes can be coimmunopre-
cipitated from extracts of these membranes. Biglycan is lo-
calized on the muscle cell surface in a pattern similar to
that previously reported for a-dystroglycan (Fig. 7; Dur-
beej et al., 1998). Taken together, these results strongly
support the proposal that biglycan and dystroglycan inter-
act at the muscle cell surface.
Work in other systems has shown that biglycan can be
substituted with either chondroitin or dermatan sulfate
(Hocking et al., 1998). The enzymatic analysis in the cur-
rent study indicates that Torpedo synaptic membrane bi-
glycan is predominantly substituted with chondroitin sul-
fate A and/or C, with less or no chondroitin sulfate B
(dermatan sulfate). Further, these GAG chains are re-
quired for binding to a-dystroglycan. The specific struc-
ture of the chondroitin sulfate side chains may also be im-
portant since a-dystroglycan binds less well to articular
cartilage biglycan, which contains both chondroitin and
Figure 5. The binding of dystroglycan to biglycan is dependent
upon specific chondroitin sulfate side chains. Biglycan (or deco-
rin) was analyzed by SDS-PAGE and Coomassie Brilliant blue
staining for protein (lanes 1–5), or blot overlay assay for dystro-
glycan binding (lanes 6–10). Lanes 1 and 6, alkaline extract of
Torpedo synaptic membranes (1 mg total protein); lanes 2 and 7,
lysate of noninduced bacteria; lanes 3 and 8, lysate of induced
bacteria expressing recombinant human biglycan (QE-Bgn;
prominent band at z37 kD, arrow); lanes 4 and 9, biglycan puri-
fied from bovine articular cartilage (4 mg; Sigma Chemical Co.);
lanes 5 and 10, decorin purified from bovine articular cartilage (4 mg;
Sigma Chemical Co.). Biglycan present in electric organ binds
dystroglycan much more strongly then biglycan or decorin puri-
fied from articular cartilage (compare Coomassie staining to dys-
troglycan overlay). Note that 4 mg of purified biglycan are
present in lanes 4 and 9, compared with only 1 mg of total protein
in lanes 1 and 6, of which biglycan is estimated to be ,2%.
Figure 6. Biglycan expression at
the neuromuscular junction. Fro-
zen sections of normal adult
mouse muscle were double-
labeled with a-bungarotoxin
(Bgtx; to localize AChRs) and
antibodies to biglycan. Biglycan
immunoreactivity is distributed
over the entire periphery of the
myofibers (see also Fig. 7). Bi-
glycan immunoreactivity is also
concentrated at some neuromus-
cular junctions. Bar, 20 mm.The Journal of Cell Biology, Volume 148, 2000 808
dermatan sulfate side chains (Cheng et al., 1994). It is pos-
sible that synapse-rich tissues contain specific enzymes
that modify the chondroitin sulfate side chains. Interest-
ingly, at least one such enzyme, the chondroitin-6-sul-
fotransferase NSIST, is selectively enriched in Torpedo
electric organ and brain (Nastuk et al., 1998). Together,
these results suggest that the interaction between dystro-
glycan and biglycan may be highly regulated through post-
translational modification.
Our studies indicate that the a-dystroglycan–binding
site for biglycan is distinct from that which binds agrin,
laminin, and perlecan. Dystroglycan binding has been
mapped to G-domains in each of these basal lamina pro-
teins (Campanelli et al., 1996; Gesemann et al., 1996; Hopf
and Hoch, 1996; Talts et al., 1999). Further, this binding
requires O-linked glycosylation of a-dystroglycan, which
occurs in the middle one-third of the molecule (Brancac-
cio et al., 1995; Fig. 8). In contrast, biglycan does not
contain a G-domain and binds to a COOH-terminal, non-
glycosylated a-dystroglycan fragment. Together, these ob-
servations suggest that a-dystroglycan could interact si-
multaneously with a G-domain–containing protein and
biglycan. These findings also raise the possibility for an al-
ternative mode of association of a-dystroglycan with the
ECM. It is interesting to speculate that such a complex
could confer unique signaling and/or structural properties
to specific cell surface domains.
The identification of DAG-125 as Torpedo biglycan
rests on its size, chondroitin sulfate substitution, and se-
quence homology to mammalian biglycan (76%, 28/37
identical residues over three peptides). It should be noted
that although we purified biglycan from highly enriched
postsynaptic fractions, its biochemical properties indicate
that it is an ECM protein. Biglycan is a member of the
SLRP family that includes decorin, fibromodulin, lumican,
keratocan, PRELP, osteoadherin, epiphycan, and osteo-
glycin (reviewed in Iozzo, 1998). The SLRPs have been
further subdivided into three classes based upon se-
quence comparison, phylogenetic relationships, and ge-
nomic structure. Biglycan and the predominantly derma-
tan sulfate proteoglycan, decorin, comprise one class (Hocking
et al., 1998). Biglycans from rodent, rabbit, dog, sheep,
cow, horse, and human are .95% identical. In contrast,
Figure 7. Upregulation of biglycan expression in dystrophic mus-
cle. Frozen sections of normal (wt) and mdx muscle from 6-wk-
old mice were mounted on the same slides and incubated with
rabbit antibiglycan (wt and mdx) as described in Materials and
Methods. The overall pattern of immunoreactivity was similar in
both cases. However, the expression of biglycan was elevated in
mdx as compared with normal muscle. Very low levels of staining
were observed when either normal (control) or mdx muscle sec-
tions (not shown) were incubated with nonimmune rabbit IgG in
the first layer. Similar results were obtained in sections prepared
from two other animals. Bar, 20 mm.
Figure 8. A model of a-dystroglycan interactions in the muscle
plasma membrane. a-Dystroglycan binds the G-domain contain-
ing proteins agrin, laminin, and perlecan in a manner that re-
quires glycosylation of the mucin-like middle third of the mole-
cules. Biglycan, in a fashion dependent on its chondroitin sulfate
side chains, binds to the protein core of the COOH-terminal
third of a-dystroglycan. See text for details.Bowe et al. Biglycan Associates with a-Dystroglycan 809
human decorin and biglycan are only 55% identical. The
three peptides from Torpedo DAG-125 are 51% identical
to human decorin. Thus, it is possible that DAG-125 is a
Torpedo decorin or a primitive SLRP that combines func-
tions of this molecule and biglycan (Blaschke et al., 1996).
At present, this issue cannot be resolved, since neither bi-
glycan nor decorin have been cloned from Torpedo. How-
ever, based upon the stronger sequence homology and
our preliminary observations that biglycan more closely
matches the distribution of a-dystroglycan in rodent mus-
cle (Mendis, D.B., and J.R. Fallon, unpublished observa-
tions), we favor the identification of DAG-125 as biglycan.
Our results show that biglycan binding to a-dystrogly-
can is mediated by its GAG chains. However, it seems
likely that the biglycan protein core will also play an im-
portant role in muscle. For example, collagen I binding to
decorin is mediated wholly by the protein core, mainly by
leucine-rich repeats #4–6 (Svensson et al., 1995; Kresse et al.,
1997). Decorin null mice have fragile skin and defects in
collagen fibril structure (Danielson et al., 1997). Biglycan
also binds to collagen I, however, the affinity is .100-fold
less, and collagen I fibril defects are not observed in bigly-
can null mice (Schonherr et al., 1995; Xu et al., 1998). Fur-
ther, both biglycan and decorin bind to TGFb via their
cores, raising the possibility that these SLRPs could be in-
volved in the presentation and/or sequestration of growth
factors. A signaling role for this class of molecules has
been suggested by the finding that nanomolar concentra-
tions of decorin directly bind to and activate EGF recep-
tors (Patel et al., 1998). It also remains possible that an in-
teraction between the biglycan core and a-dystroglycan
could have been missed in the assays used here. We are
currently using properly folded recombinant biglycan core
protein to test its binding to a-dystroglycan and other
DAPC components.
Although we discovered biglycan in a highly enriched
synaptic fraction and it is expressed at the neuromuscular
junction, at present we do not know its function at these
sites. Several studies have shown that chondroitin sulfate
proteoglycans are important for postsynaptic differentia-
tion (Gordon et al., 1993; Mook-jung and Gordon, 1995;
Bowen et al., 1996), although the proteoglycans involved
have not been identified. Further, a-dystroglycan may
function in the formation of AChR clusters. It is possible
that biglycan could play a role here as well. Finally, it is
noteworthy that MuSK (muscle-specific kinase) is the
agrin signaling receptor, but agrin does not bind it directly.
The signaling properties of SLRPs in other systems invite
speculation that biglycan could be an element in the hypo-
thetical MuSK/coreceptor complex, (Glass et al., 1996) ei-
ther by binding MuSK directly or presenting a growth fac-
tor-like ligand to it.
Our findings could also have important implications for
understanding muscular dystrophy. The integrity of the
DAPC and its association with the ECM are essential for
muscle cell viability. The binding of biglycan to a-dystro-
glycan represents an entirely new mode for DAPC–ECM
association. This mode could act in concert with, or as an
alternative to, binding via the G-protein–containing basal
lamina proteins agrin, perlecan, and laminin. Such an al-
ternative pathway for DAPC association with the ECM
could provide a new avenue for developing therapeutic in-
terventions for muscular dystrophies and perhaps other
neuromuscular disorders.
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